Evidence map›Paper›PMID 40594867›Full record

ArticleScientific reports2025

Identification of a ferroptosis related genes signature and GDF15 contributing to a new perspective for the diagnosis of CRPC.

Yuanyuan Shao, Xiaoli Li, Jiaolong Liu, Zhongjian Qiu, Taijian Zhang, Nan Li, Jianmeng Hu, Fuding Lu, Zhiguo Zhu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuanyuan Shao *Department of Urology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
Xiaoli Li *Department of Andrology, The Seventh Affiliated Hospital, Sun Yet-sen University, Shenzhen, Guangdong, China.
Jiaolong Liu *State Key Laboratory of Reproductive Medicine and Offspring Health, Shandong University, Jinan, Shandong, China.
Zhongjian QiuDepartment of Urology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
Taijian ZhangState Key Laboratory of Reproductive Medicine and Offspring Health, Shandong University, Jinan, Shandong, China.
Nan LiMedical Research Center, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
Jianmeng HuMedical Research Center, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
Fuding LuDepartment of Andrology, The Seventh Affiliated Hospital, Sun Yet-sen University, Shenzhen, Guangdong, China. lufuding@sysush.com.
Zhiguo ZhuDepartment of Urology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China. zhuzhiguo@mail.jnmc.edu.cn.

Funding

China Postdoctoral Science Foundation 2023M731309Guangdong Basic and Applied Basic Research Foundation 2020A1515110946Jining Key Research and Development Foundation 2023YXNS023PhD Research Foundation of Affiliated Hospital of Jining Medical University 2022-BS-001Research Fund for Academician LinHe New Medicine JYHL2022FMS09
6 · The paper itself

Abstract

Prostate cancer (PCa) is a highly prevalent malignancy among men. Castration-resistant prostate cancer (CRPC) is the main pathological type leading to the death of patients. Due to the lack of effective early diagnostic biomarkers, the treatment of CRPC is often lagging. Ferroptosis is a new discovered pathway of cell death. The diagnostic value of ferroptosis-related genes for CRPC is still uncertain. In this study, we identified 10 differently expressed FRGs between 145 hormone-sensitive PCa (HSPC) and 49 CRPC. A novel ferroptosis-related genes (FRGs) signature was constructed using seven FRGs (ABCC5, ACSL1, AKR1C3, CAMKK2, GDF15, PDSS2, and ZFP36), which could distinguish CRPC from HSPC with area under the ROC curve (AUC) = 0.93. This result was confirmed in an independent validation cohort with AUC = 0.90, F1 score = 0.85. Among the seven FRGs, GDF15 independently predicted CRPC with the good performance (AUC = 0.84). Moreover, GDF15 could effectively distinguish PCa from normal tissues (AUC = 0.79 and 0.83 in two cohorts). Two distinct ferroptosis profiles were discovered, and FRGs signature and GDF15 could also effectively distinguish them. GDF15 expression level shows an inverted U-shape with disease progression (normal, HSPC, CRPC). Although GDF15 expression was decreased in CRPC cells, overexpression of GDF15 still facilitates CRPC cells migration and invasion in vitro. Our findings suggest that this novel FRGs signature and GDF15 could be robust biomarkers for predicting CRPC in clinical practice.

Indexed as

Biomarkers, TumorFerroptosisGrowth Differentiation Factor 15Prostatic NeoplasmsAgedCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedROC CurveBiomarkers, TumorGDF15 protein, humanGrowth Differentiation Factor 15BiomarkerCastration-resistant prostate cancerDiagnosticFerroptosisGDF15

Identifiers

PMID40594867
PMCPMC12217955

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.